# Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition

> **NCT05336279** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 28 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** famitinib malate T(5 mg*4)、famitinib malate R(20 mg)
- **DRUG:** famitinib malate T(5 mg*4)、famitinib malate R(20 mg)

## Key facts

- **NCT ID:** NCT05336279
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-11
- **Primary completion:** 2022-05-27
- **Final completion:** 2022-06-20
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05336279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05336279, "Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT05336279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*